Literature DB >> 30396911

Persistence of endothelial thrombomodulin in a patient with infectious purpura fulminans treated with protein C concentrate.

Pavan K Bendapudi1,2,3, Alissa Robbins4, Nicole LeBoeuf3,5, Olga Pozdnyakova3,6, Ami Bhatt7,8, Fujiko Duke4, Ryan Sells3,5, John McQuiston9, Ben Humrighouse9, Betty Rouaisnel4, Meaghan Colling1,3, Kathryn E Stephenson3,10,11, Arturo Saavedra12, Julie-Aurore Losman3,4,13,14.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30396911      PMCID： PMC6234356          DOI： 10.1182/bloodadvances.2018024430

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  22 in total

1.  An open-label study of the role of adjuvant hemostatic support with protein C replacement therapy in purpura fulminans-associated meningococcemia.

Authors:  B White; W Livingstone; C Murphy; A Hodgson; M Rafferty; O P Smith
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

Review 2.  Activated protein C: biased for translation.

Authors:  John H Griffin; Berislav V Zlokovic; Laurent O Mosnier
Journal:  Blood       Date:  2015-03-30       Impact factor: 22.113

3.  Induction of the acute-phase reaction increases heparin-binding proteins in plasma.

Authors:  E Young; T J Podor; T Venner; J Hirsh
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-08       Impact factor: 8.311

4.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis.

Authors:  S N Faust; M Levin; O B Harrison; R D Goldin; M S Lockhart; S Kondaveeti; Z Laszik; C T Esmon; R S Heyderman
Journal:  N Engl J Med       Date:  2001-08-09       Impact factor: 91.245

5.  Protein C substitution in sepsis-associated purpura fulminans.

Authors:  E Rintala; M Kauppila; O P Seppälä; L M Voipio-Pulkki; V Pettilä; V Rasi; P Kotilainen
Journal:  Crit Care Med       Date:  2000-07       Impact factor: 7.598

6.  Use of protein-C concentrate, heparin, and haemodiafiltration in meningococcus-induced purpura fulminans.

Authors:  O P Smith; B White; D Vaughan; M Rafferty; L Claffey; B Lyons; W Casey
Journal:  Lancet       Date:  1997-11-29       Impact factor: 79.321

7.  Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients.

Authors:  Alex Veldman; Doris Fischer; Flora Y Wong; Wolfhart Kreuz; Michael Sasse; Bruno Eberspächer; Ulrich Mansmann; Rudolf Schosser
Journal:  Crit Care       Date:  2010-08-19       Impact factor: 9.097

8.  Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells.

Authors:  H Ishii; H Uchiyama; M Kazama
Journal:  Thromb Haemost       Date:  1991-05-06       Impact factor: 5.249

9.  Assessment of the interplay between blood and skin vascular abnormalities in adult purpura fulminans.

Authors:  Nicolas Lerolle; Agnes Carlotti; Keira Melican; Flore Aubey; Marc Pierrot; Jean-Luc Diehl; Vincent Caille; Guillaume Hékimian; Sophie Gandrille; Chantal Mandet; Patrick Bruneval; Guillaume Dumenil; Delphine Borgel
Journal:  Am J Respir Crit Care Med       Date:  2013-09-15       Impact factor: 21.405

10.  Use of 16S rRNA gene sequencing for rapid identification and differentiation of Burkholderia pseudomallei and B. mallei.

Authors:  Jay E Gee; Claudio T Sacchi; Mindy B Glass; Barun K De; Robbin S Weyant; Paul N Levett; Anne M Whitney; Alex R Hoffmaster; Tanja Popovic
Journal:  J Clin Microbiol       Date:  2003-10       Impact factor: 5.948
View more
  1 in total

Review 1.  Surgical outcomes in adults with purpura fulminans: a systematic review and patient-level meta-synthesis.

Authors:  Kevin M Klifto; Caresse F Gurno; Michael J Grzelak; Stella M Seal; Mohammed Asif; C Scott Hultman; Julie A Caffrey
Journal:  Burns Trauma       Date:  2019-10-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.